FLT3 and acute myeloid leukemia: The KOMET-008 phase 1 trial included an arm testing the combination of ziftomenib and gilteritinib for FLT3-ITD-mutated R/R AML, showing significant benefits for AML patients with NPM1m or KMT2Ar.